Hangzhou Bio-Sincerity Pharma-Tech Secures Clinical Trial Approval for Novel Drug BIOS0629-109

Stock News

Jul 02

An announcement from Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. (SZSE: 301096) reveals that its innovative drug, BIOS0629-109 tablets, has received a clinical trial approval notice from the National Medical Products Administration (NMPA).

This drug candidate, developed in collaboration with Zhejiang Zhong Shen Innovation Pharmaceutical Technology Co., Ltd., is classified as a Category 1 chemical drug.

BIOS0629-109 is a novel XPO1 inhibitor intended for the treatment of advanced malignant tumors.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1153829989"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1153829989\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1153829989?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-02 21:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1153829989","market":"nz","top_or_hot":-1,"title":"Hangzhou Bio-Sincerity Pharma-Tech Secures Clinical Trial Approval for Novel Drug BIOS0629-109","media":"Stock News","content":"<p>An announcement from <b>Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd.</b> (<b>SZSE: 301096</b>) reveals that its innovative drug, BIOS0629-109 tablets, has received a clinical trial approval notice from the National Medical Products Administration (NMPA).<br><br>This drug candidate, developed in collaboration with Zhejiang Zhong Shen Innovation Pharmaceutical Technology Co., Ltd., is classified as a Category 1 chemical drug.<br><br>BIOS0629-109 is a novel XPO1 inhibitor intended for the treatment of advanced malignant tumors.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hangzhou Bio-Sincerity Pharma-Tech Secures Clinical Trial Approval for Novel Drug BIOS0629-109</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHangzhou Bio-Sincerity Pharma-Tech Secures Clinical Trial Approval for Novel Drug BIOS0629-109\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-07-02 21:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>An announcement from <b>Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd.</b> (<b>SZSE: 301096</b>) reveals that its innovative drug, BIOS0629-109 tablets, has received a clinical trial approval notice from the National Medical Products Administration (NMPA).<br><br>This drug candidate, developed in collaboration with Zhejiang Zhong Shen Innovation Pharmaceutical Technology Co., Ltd., is classified as a Category 1 chemical drug.<br><br>BIOS0629-109 is a novel XPO1 inhibitor intended for the treatment of advanced malignant tumors.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"159992","symbol_name":"创新药","start_time":0,"source_url":"","article_id":"1153829989","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1153829989","pubTimestamp":1782999338,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"An announcement from Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. (SZSE: 301096) reveals that its innovative drug, BIOS0629-109 tablets, has received a clinical trial approval notice from the National...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159992":"创新药","301096":"百诚医药","BK0216":"研究试验","06978":"永泰生物-B","BK1161":"生物科技","BK1574":"生物医药B类股"},"translate_title":"杭州生物诚信制药获得新药BIOS0629-109临床试验批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159992":1,"301096":1,"06978":1},"content_text":"An announcement from Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. (SZSE: 301096) reveals that its innovative drug, BIOS0629-109 tablets, has received a clinical trial approval notice from the National Medical Products Administration (NMPA).This drug candidate, developed in collaboration with Zhejiang Zhong Shen Innovation Pharmaceutical Technology Co., Ltd., is classified as a Category 1 chemical drug.BIOS0629-109 is a novel XPO1 inhibitor intended for the treatment of advanced malignant tumors.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}